Modern Guidelines Offer Roadmap for Acute Pulmonary Embolism Care

DALLAS and WASHINGTON, Feb. 19, 2026 — Early detection and prompt treatment of acute pulmonary embolism (PE), a potentially life-threatening condition where blood clots block arteries in the lungs, are critical. New clinical practice guidelines published today in Circulation and JACC, the flagship journals of the American Heart Association and the American College of Cardiology, respectively, detail comprehensive recommendations for the evaluation, management, and follow-up care for adults with acute PE.

Understanding Pulmonary Embolism

A PE typically occurs when a blood clot forms in a deep vein, usually in the leg or pelvis, travels through the heart, and lodges in a pulmonary artery. This is part of a broader condition known as venous thromboembolism (VTE). Acute PE can reduce oxygen levels in the blood, damage lung tissue, and strain the heart, potentially leading to a fatal outcome. According to the American Heart Association’s 2026 Heart Disease and Stroke Statistics, approximately 470,000 people are hospitalized with PE in the U.S. Annually, and roughly 1 in 5 high-risk patients die.¹

A New Clinical Category System

The guidelines introduce a new Acute PE Clinical Category system, classifying patients into five categories (A-E) based on the severity of their symptoms and risk for adverse outcomes. Patients in Categories A and B have mild or no symptoms and a low risk of complications, often allowing for safe discharge from the emergency department. Categories C-E represent individuals with more severe symptoms and a higher risk, requiring hospitalization.

Risk Factors for Acute PE

Prompt diagnosis is essential, but can be challenging as symptoms – such as shortness of breath, chest pain, rapid heartbeat, fainting, and dizziness – can mimic other conditions. Factors that increase the risk of VTE, and therefore PE, include:

• Major surgery or trauma
• Hospitalization
• Prolonged immobility (e.g., bed rest or long travel)
• Pregnancy and the postpartum period (within 6 weeks after delivery)
• Use of oral contraceptives or estrogen treatment
• Obesity (BMI ≥ 30)
• Smoking
• Atherosclerotic cardiovascular disease
• Cancer
• Thrombophilias (blood clotting disorders)
• Age (risk increases after age 40)

Diagnostic Testing

For patients with a low or intermediate probability of acute PE, a blood test to measure D-dimer, a protein fragment released when the body breaks down a clot, is recommended. Normal D-dimer levels suggest PE is unlikely. If D-dimer is elevated, or the clinical probability is high, imaging is necessary.

Computed tomography pulmonary angiography (CTPA) is the standard imaging test for diagnosing or ruling out acute PE. For patients unable to undergo CTPA (e.g., due to iodine allergy), a lung ventilation/perfusion scan is an alternative.³

Treatment Strategies

Anticoagulants (blood thinners) are the primary treatment for confirmed acute PE. Direct oral anticoagulants (DOACs) – such as rivaroxaban, apixaban, edoxaban, or dabigatran – are generally preferred over vitamin K antagonists like warfarin due to their safety, ease of use, and reduced bleeding risk. DOACs are not recommended during pregnancy, while low-molecular-weight heparin or unfractionated heparin are safe options.

Patients in Categories D-E may require advanced treatments, including clot-dissolving drugs (administered intravenously or via catheter), mechanical clot removal, or surgical embolectomy. The guidelines similarly address sedation, ventilation, and circulatory support for critically ill patients.³

Follow-Up Care

Comprehensive follow-up is crucial:

• Early Follow-Up: All patients should have a follow-up visit or communication within one week of discharge to review the treatment plan and check for complications.
• Additional Follow-Up: A clinic visit should occur by three months to determine the duration of anticoagulant therapy and assess ongoing symptoms.
• Long-Term Monitoring: Patients should be screened for chronic thromboembolic pulmonary disease (CTEPD) – a condition where persistent clots cause long-term blockage – at every visit for at least one year.
• Ongoing Anticoagulation Review: For patients continuing anticoagulants beyond 3-6 months, the risks and benefits should be periodically reassessed.

Additional considerations include addressing psychological health (depression, anxiety, PTSD), encouraging early walking to promote blood flow, providing precautions for travel (frequent movement, compression socks), and counseling women of childbearing age about contraception and anticoagulation options during pregnancy.

The Future of PE Management

“We anticipate that decisions guided by these recommendations will result in more rapid diagnosis and application of effective, evidence-based treatments, leading to better outcomes, such as decreased risk of death and disability, for people with acute pulmonary embolism,” said Mark A. Creager, M.D, FAHA, FACC, chair of the guideline writing committee.¹

References

1. American Heart Association. Interventional Therapies for Acute Pulmonary Embolism. Published October 4, 2019. Accessed February 19, 2026.
2. American Heart Association/American College of Cardiology. Pulmonary Embolism: A Clinical Approach. February 1, 2025. Accessed February 19, 2026.
3. ACR. Management of Acute Pulmonary Embolism. Accessed February 19, 2026.